Shares of Onyx Pharmaceutical soaring after it received- and rejected a $10 billion takeover offer from biotech Amgen. Its shares were already up 31 percent over the past 12 months. Onyx says Amgen's offer of $120 a share is too low. That offer represents a premium of 38 percent based on Onyx's closing price on Friday. And Onyx may have a point. Deutsche Bank analyst Robin Karnauskas says in a note: "From our M&A valuation, we expect higher bids for Onyx of at least $140."moreless
Please read the following before uploading
Do not upload anything which you do not own or are fully licensed to upload. The images should not contain any sexually explicit content, race hatred material or other offensive symbols or images. Remember: Abuse of the TV.com image system may result in you being banned from uploading images or from the entire site – so, play nice and respect the rules!